Insulin resistance metabolomic profile in non-diabetic women with systemic lupus erythematosus

Patients with systemic lupus erythematosus (SLE) have a higher prevalence of insulin resistance (IR) and metabolic syndrome (MetS) than controls. To evaluate IR in non-diabetic women with SLE by means of biomarkers using high-throughput metabolomic techniques. Cross-sectional study in patients with...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Gaceta médica de México 2021, Vol.157 (6), p.594-598
Hauptverfasser: Mendoza-Pinto, Claudia, García-Carrasco, Mario, Méndez-Martínez, Socorro, Munguía-Realpozo, Pamela, Etchegaray-Morales, Ivet, Díaz-Merino, Gerardo, Soto-Santillán, Pamela, Escamilla-Márquez, Marco A, Ruiz-Arguelles, Alejandro
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Patients with systemic lupus erythematosus (SLE) have a higher prevalence of insulin resistance (IR) and metabolic syndrome (MetS) than controls. To evaluate IR in non-diabetic women with SLE by means of biomarkers using high-throughput metabolomic techniques. Cross-sectional study in patients with SLE. A metabolomic approach was employed using ultra-high performance liquid chromatography coupled with high-resolution mass spectrometry. MetS was evaluated according to NCEP-ATP III criteria. Seventy patients with SLE were included, out of whom 45 (64.2%) and 27 (38.5%) had IR and MetS, respectively. Patients with IR had a higher body mass index and hypertension more often than those without IR. Chronic damage and disease activity were not related to IR. A Quantose-IR score ≥ 63 was more common in patients with MetS (81.5 vs. 53.5%; p = 0.02). Quantose-IR score was also correlated with the number of criteria for MetS (r: 0.35; p = 0.003). In non-diabetic women with SLE, the prevalence of IR based on Quantose-IR score was 64.2%.
ISSN:0016-3813
DOI:10.24875/GMM.M21000622